Video

Dr. Jennifer Brown on Ibrutinib and Idelalisib for CLL

Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses the treatment of chronic lymphocytic leukemia with ibrutinib, idelalisib, and other agents.

Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses the treatment of chronic lymphocytic leukemia with ibrutinib, idelalisib, and other agents.

Ibrutinib is a covalent Bruton's tyrosine kinase inhibitor that has demonstrated a 70% response rate, according to Brown. In treatment-naïve patients, ibrutinib showed 90% progression-free survival over two years and 75% over two years in relapsed patients.

Idelalisib is an inhibitor of the delta isofrom of PI3K and showed a high response rate in relapsed refractory CLL. Idelalisib also demonstrated a PFS of 16 months in a phase I study. Brown notes that no large phase II study has begun yet and that other BTK and PI3K inhibitors are behind in development.

Dasatinib and everolimus have shown efficacy in other diseases but have not produced great results in CLL as single agents.

Syk inhibitors, such as fostamatinib, are also in development for CLL, Brown says.

Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine